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Abstract
Background: A primary characteristic of complex genetic diseases is that affected individuals tend to cluster in
families (that is, familial aggregation). Aggregation of the same autoimmune condition, also referred to as familial
autoimmune disease, has been extensively evaluated. However, aggregation of diverse autoimmune diseases, also
known as familial autoimmunity, has been overlooked. Therefore, a systematic review and meta-analysis were
performed aimed at gathering evidence about this topic.
Methods: Familial autoimmunity was investigated in five major autoimmune diseases, namely, rheumatoid arthritis,
systemic lupus erythematosus, autoimmune thyroid disease, multiple sclerosis and type 1 diabetes mellitus.
Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) guidelines were followed. Articles
were searched in Pubmed and Embase databases.
Results: Out of a total of 61 articles, 44 were selected for final analysis. Familial autoimmunity was found in all the
autoimmune diseases investigated. Aggregation of autoimmune thyroid disease, followed by systemic lupus
erythematosus and rheumatoid arthritis, was the most encountered.
Conclusions: Familial autoimmunity is a frequently seen condition. Further study of familial autoimmunity will help
to decipher the common mechanisms of autoimmunity.
Keywords: Autoimmune diseases, familial autoimmunity, aggregation, genetic epidemiology, autoimmune
tautology
Background
Autoimmune diseases (ADs) are chronic conditions
initiated by the loss of immunological tolerance to self-
antigens; they represent a heterogeneous group of disor-
ders that afflict specific target organs or multiple organ
systems [1]. The chronic nature of these diseases places a
significant burden on the utilization of medical care,
increases direct and indirect economic costs, and
diminishes quality of life. The estimated incidence of ADs
is approximately 80 per 100,000 person years and their
prevalence could be well beyond 3% of the population [2].
Most of the ADs asymmetrically affect middle-aged
women and are among the leading causes of death for this
group of patients. Although the frequency of ADs varies
between countries [3], various studies have shown that, for
some ADs, associations are found across populations [4].
ADs share several clinical signs and symptoms (that is,
subphenotypes), physiopathological mechanisms, and
genetic factors. These shared characteristics have been
grouped under the term autoimmune tautology [5-10]. In
clinical practice two conditions support this theory,
namely, polyautoimmunity and familial autoimmunity,
both of which are considered as being part of the ‘kaleido-
scope of autoimmunity’ [11-14]. Whereas polyautoimmu-
nity is the presence of two or more ADs in a single
patient, familial autoimmunity occurs when relatives from
a nuclear family present diverse ADs [9] (Figure 1). These
conditions indicate that similar genetic, epigenetic, and
environmental factors influence the development of
ADs [7]. The best examples of polyautoimmunity are the
multiple autoimmune syndrome (MAS), which occurs
when a patient has three or more ADs [15,16], and the* Correspondence: juan.anaya@urosario.edu.co
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Figure 1 How do autoimmune diseases cluster in families? A) Familial autoimmune disease. This classical concept indicates the same AD
in diverse FDRs. In this case, a proband and a FDR (that is, the father) present with T1D. B) Familial autoimmunity. This new concept
corresponds to the presence of different ADs in a nuclear family. C) Multiple autoimmune syndrome. This condition refers to the presence of
three or more autoimmune diseases in the same subject. In this case, two brothers met criteria for the syndrome. Moreover, this pedigree
also meets criteria for familial autoimmunity. D) Polyglandular autoimmune syndrome type II. In this family, however, familial autoimmune
disease and familial autoimmunity coexist. The results of HLA genes (that is, A, B, DRB1, DQB1) typing are shown in colors (by reverse dot
blot using InnoLipa Kit). A suggestive linkage among the HLA loci is observed. In these diagrams, people are represented by symbols: circles
for female and squares for male, and the bottom line represents the offspring of the couple above. Solid symbols represent affected
individuals. Symbol with a diagonal line indicates deceased individual. AdD, Addison’s disease; AITD, autoimmune thyroid disease; APS,
antiphospholipid syndrome; FDRs, first degree relative; MS, multiple sclerosis; PA, pernicious anemia; SLE, systemic lupus erythematosus; SS,
Sjögren’s syndrome; T1D, type 1 diabetes; VIT, vitiligo.
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polyglandular autoimmune syndromes type II, III and IV
[17], which are in fact MAS.
ADs do not begin at the moment they become clini-
cally apparent but several years before. This implies that
there is a chance to predict autoimmunity. Over the
years, several risk factors have been associated with the
onset of ADs. Among these the most widely studied are
female gender [18], specific alleles at HLA and non-
HLA loci [2,19] and some environmental agents [20,21].
In addition, the presence of auto antibodies may also
predict specific clinical manifestations, disease severity
and disease progression [22-27]. As reviewed by Tobon
et al. [5] many auto antibodies have a predictive ability
and they can be serologically evaluated long before the
appearance of clinical disease. Thus, identification of
these markers as well as a family history of autoimmu-
nity and evaluation of their predictive value could be
useful for personalized medicine.
A primary characteristic of complex diseases is that
they are likely to aggregate in families (that is, familial
aggregation, also referred to as recurrence risk or lambda,
l). The aggregation of a phenotype is observed when a
disease occurs at a higher frequency in the relatives of an
affected individual as compared with the frequency
observed in the general population. Values of l >1.0 indi-
cate aggregation [9]. Aggregation of the same autoim-
mune condition, also referred to as familial autoimmune
disease, has been extensively evaluated. However, aggre-
gation of diverse autoimmune diseases, also known as
familial autoimmunity, has been overlooked (Figure 1).
Therefore, a systematic review and meta-analysis were
performed aimed at gathering evidence about this topic.
Methods
Systematic review
A literature search was done even though ‘familial auto-
immunity’ is not a Medical Subject Headings (MeSH)
term. Nevertheless, the search was done in the electro-
nic databases Medline and Embase, and included arti-
cles, from 1966 for the former and 1980 for the latter,
up to June 2012. The search strategy was limited to
humans and included the words ‘(familial OR clustering
OR aggregation)’ AND ‘autoimmunity followed by each
of the diseases we have focused on: ‘multiple sclerosis,’
‘diabetes mellitus, Type 1,’ ‘arthritis, rheumatoid’ and
‘lupus erythematosus, systemic’ using MeSH terms and
key words for ‘autoimmune thyroid disease’. In order
not to miss potentially eligible studies we used wild
cards for the words familial, clustering and aggregation
in the following manner: famil*, aggrega* and cluster*.
No language restrictions were used. Articles were
included if they fulfilled the following conditions: ADs
diagnosis was carried out according to international cri-
teria or through international classification of diseases,
articles were published as full articles and, as mentioned
earlier, if ADs in first degree relatives (FDRs) were dif-
ferent than in the proband. Studies were excluded if
they only referred to autoantibody prevalence, if a clear
cut distinction between diseases was not possible, if it
was not possible to distinguish between probands and
FDRs, if the studies were case reports, and if they dealt
with a single family. Unpublished data were also
excluded. Eligibility assessment was done by a primary
reviewer who screened all titles and abstracts of publica-
tions. Retrieved articles were rejected if eligibility criteria
were not met and a secondary reviewer was consulted in
cases in which eligibility criteria were unclear. Refer-
ences from the articles that seemed to be relevant for
our review were hand-searched. All articles were
assessed according to the Oxford Centre for Evidence-
based Medicine 2011 Levels of Evidence [28]. The
search returned articles in which familial autoimmunity
was assessed in other ADs and they were included.
From each study we extracted data including total num-
ber of FDRs, numbers of FDRs affected, prevalence of
ADs and, where possible, extraction of crude and
adjusted measures of association, that is, odds ratio
(OR) or risk ratio (RR). With the prevalences extracted,
aggregation for different ADs across the five index dis-
eases mentioned earlier was calculated by dividing the
prevalence of a given AD in FDRs by the prevalence in
the general population (lrelatives). We extracted data on
prevalences from five reports [2,29-32]. Inclusion criteria
for the meta-analyses were applied to publications that
provided epidemiological data on risk factors, RR and
OR with confidence intervals (CI), or that provided
information that allowed us to calculate these data. If
the study did not report the number of subjects in each
group, either the RR or the OR with the CI, must have
been reported in order for them to be included in the
meta-analyses calculations.
In order to study aggregation, we determined world-
wide prevalences of ADs from five studies mentioned
earlier [2,29-32]. If a range was reported, we arbitrarily
calculated the mean.
Meta-analyses
Data were analyzed using the Comprehensive Meta-
Analysis Version 2 program (Biostat, Englewood, NJ,
2004). Calculations were carried out for the whole
group of articles depending on the binary data available
for any AD: number of subjects and risk data (OR and
RR with the corresponding 95% CI). Effect size was cal-
culated based on studies that reported an OR with its
respective 95% CI and from raw data given by case-con-
trol and cohort studies. If raw data from cohort studies
were available, a second effect size was calculated with
studies that only showed the RR and the respective 95%
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CI. Different study designs were used to compute the
same effect size since the effect size had the same mean-
ing in all studies and was comparable in relevant
aspects. In order to perform the analyses, the association
measures were transformed to log values, and then the
results were converted back to ratio values for presenta-
tion. This approach prevented the omission of studies
that used an alternative measure. Two types of meta-
analyses were done in order to analyze autoimmunity as
a trait. First, a given AD in FDRs was analyzed through
all the studies regardless of the AD of the proband. The
second type of meta-analysis analyzed ADs in FDRs
through all the studies from a specific AD present in
the proband.
Additional meta-analyses were done for studies with
complex data structures and non-cumulative results as
the information for the different effects was not totally
independent. This is the case for studies reporting mul-
tiple independent subgroups, that is, aggregation for son
and daughter separately, within a study. A flow diagram
of the current study is shown in Figure 2.
ORs were grouped by weighing individual ORs by the
inverse of their variance. For each analysis, the final
effect OR and 95% CI were obtained by means of the
random effect model, which was preferred because it
accepts distributions of true effect sizes rather than one
true effect and assigns a more balanced weight to each
study. It was also used because all the studies were con-
sidered to be unequal in terms of specific ADs.
Heterogeneity was calculated by means of Higgins’s
(I2) tests. The variance between studies was estimated
by the DerSimonian and Laird method. The I2 test
showed the proportion of observed dispersion that was
real rather than spurious and was expressed as a ratio
ranging from 0% to 100%. I2 values of 25%, 50%, and
75% were qualitatively classified as low, moderate, and
high, respectively. Publication bias was determined using
Funnel plots and Egger’s regression asymmetry tests.
Results
Studies retrieved
After discarding duplicates, the search in both databases
retrieved 2,552 articles. In a first assessment we consid-
ered 61 articles to be eligible. In a second screening 17
of these articles were not eligible due to reporting
inconsistencies, such as not distinguishing between pro-
bands and FDRs. As we did not identify other articles
from the reference lists, only 44 articles met eligibility
criteria [32-75]. Figure 3 and Table 1 summarize the
search results. Although ankylosing spondylitis (AS) is
considered an auto-inflammatory more than autoim-
mune disease [76], it was included in the results since it
was found to aggregate in families. Most of the studies
found lacked controls and had a small sample size,
which is reflected in low grading according to the 2011
levels of evidence from the Oxford Centre for Evidence-
based Medicine [28]. Detailed information is shown in
Table 2.
Autoimmune thyroid disease
Three articles assessed familial autoimmunity for auto-
immune thyroid disease (AITD) [33-35]. AITD encom-
passes Graves’ disease as well as Hashimoto’s thyroiditis
with the latter being the most common cause of
acquired hypothyroidism [77]. Moreover, AITD is the
most common AD [78]. Various studies have shown
that AITD coexists with other ADs in the same subject
[79,80] and it has also been shown that there is familial
clustering of AITD in FDRs, particularly in female rela-
tives [81]. Boelaert et al. [33] described familial autoim-
munity among probands with Hashimoto’s thyroiditis or
Graves’ disease. Both ADs were significantly associated
with the presence of type 1 diabetes mellitus (T1D),
rheumatoid arthritis (RA), pernicious anemia (PA), sys-
temic lupus erythematosus (SLE), celiac disease (CD),
vitiligo (VIT) and multiple sclerosis (MS). Only Graves’
disease was associated with Addison’s disease (AdD) and
inflammatory bowel disease (IBD). Compared with the
general population, familial autoimmunity in Graves’
disease probands disclosed PA as the strongest associa-
tion (RR: 14.1; 95% CI: 11.48 to 17.03), followed by RA
(RR: 13.5; 95% CI: 12.32 to 14.86).
Hemminki et al. [34] assessed familial autoimmunity
only in probands with Graves’ disease from Sweden. To
calculate familial risk within a large community based
cohort they calculated standardized incidence ratios
(SIR) as the ratio between the observed and the
expected frequency for each disease. A value over one
indicates an increased frequency of what is expected
whereas a value below one indicates a decreased fre-
quency. The analysis was stratified according to the
FDR involved. For a single parent affected, Hashimoto’s
disease, PA, and RA were the only diseases significantly
associated, having a SIR of 2.04, 1.82 and 1.48, respec-
tively, thus showing an increased frequency of what is
expected. Significant associations for singleton siblings
were found for T1D, discoid lupus and localized sclero-
derma, having a SIR of 2.14, 6.03 and 6.62, respectively.
If a parent and a sibling were affected with the same
AD, the significant association was between Hashimoto’s
disease with a SIR of 37.41 and SLE with a SIR of 14.33
[34].
Type 1 diabetes mellitus
The search returned seven articles about T1D probands
[35-41]. AITD was responsible for the familial autoim-
munity found in most of the articles [36,40], even when
compared to control subjects [37]. Wagner et al. [38]
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replicated the results but also described the presence of
CD, psoriasis (PSO), and VIT.
Hemminki et al. [39] also reported familial autoimmu-
nity in probands with T1D. When a parent had AdD,
the SIR for T1D in offspring was 2.41. It was 2.73 for
CD, 1.83 for Graves’ disease, 2.13 for Hashimoto’s thyr-
oiditis, 3.09 for PA, 3.63 for primary biliary cirrhosis
(PBC), 2.12 for RA, 1.62 for SLE, 1.23 for ulcerative
Figure 2 Flow diagram of current study. AITD, autoimmune thyroid disease; MS, multiple sclerosis; RA, rheumatoid arthritis; SLE, systemic
lupus erythematosus; T1D, type 1 diabetes.
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colitis (UC), and 1.23 for Wegener’s granulomatosis
(WG). Only the presence of AdD, CD or Graves’ disease
in singleton siblings was associated with T1D in pro-
bands. Likewise, when a parent and sibling had RA, the
SIR for T1D was 5.34 [39].
Systemic lupus erythematosus
Four articles assessed familial autoimmunity in SLE pro-
bands. Alarcon-Segovia et al. evaluated familial aggrega-
tion in the ‘Grupo Latinoamericano de Estudio de
Lupus’ (GLADEL) [42]. They found that among all
family members who had any AD, 6.7% had RA, 2%
AITD and other ADs at a lesser frequency. In FDR (n =
114) with ADs, 28% (n = 32) had RA and 16% (n = 32)
had AITD [42]. Likewise, an increased frequency of
familial autoimmunity was found in SLE probands com-
pared with population prevalence. Priori et al. [43]
found an OR of 4.6 (95% CI 1.94 to 11.1) in a multivari-
ate analysis of familial autoimmunity in FDR of SLE
patients. They reported AITD as the most frequent dis-
ease with eight cases, followed by RA with five cases,
VIT with three cases and T1D with two cases. PSO fre-
quency was higher among non-autoimmune controls.
Sjögren´s syndrome (SS) as well as AITD were described
Figure 3 Flowchart summarizing the search results.
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Table 1 Significant associations of autoimmune diseases in first degree relatives.
Proband´s disease Author Disease in first degree relatives References
Autoimmune thyroid disease Boelaert et al. AdD, CD, IBD, MG, MS, PA, RA, SLE, T1D, VIT [33]
Hemminki et al. In parent: AdD, IIM, MG, PA, RA, T1D, UC [34]
In sibling: Discoid lupus erythematosus, localized SSc, T1D
In parent and sibling: SLE
Type 1 diabetes Bottazo et al. AITD [36]
Anaya et al. AITD [37]
Wagner et al. AITD,CD, PSO, RA, VIT [38]
Hemminki et al. In parent: AdD, AITD, AS, CD, PA, PBC, RA, SLE, UC, WG [39]
In sibling: AdD, AITD, CD
In parent and sibling: RA
Lebenthal et al. AITD, CD [41]
Systemic lupus erythematosus Criswell et al. AITD [35]
Alarcon-Segovia et al. AITD, IIM, RA, SSc [42]
Priori et al. AITD, RA, T1D, VIT [43]
Corporaal et al. MS, RA [44]
Rheumatoid arthritis Lin et al. AITD, T1D, [45]
Thomas et al. T1D [46]
Hemminki et al. In parent: AITD, AS, Localized SSc, PA, PSO, SLE, SS, SSc, WG [47]
In sibling: PSO, SLE
Jawaheer et al. AITD [48]
Multiple sclerosis Barcellos et al. AITD, PSO, RA, T1D [32]
Criswell et al. PSO [35]
Broadley et al. AITD [49]
Deretzi et al. AITD, IBD, PSO, T1D [50]
Heinzlef et al. AITD, RA, T1D, VIT [51]
Henderson et al. AS [52]
Marrosu et al. T1D [53]
Nielsen et al. AdD, CrD, PAN, [55]
Systemic sclerosis Arora-Singh et al. AITD, RA, SLE, [57]
Hudson et al. AITD, PBC, RA, SLE, SS [58]
Koumakis et al. AITD, RA, SLE, SS [59]
Sjögren’s syndrome Reveille et al. AITD, MS, SLE, SSc [61]
Anaya et al. AITD, RA, SLE [62]
Inflammatory bowel disease Criswell et al. MS [35]
Ulcerative colitis Hemminki et al. In parent: AITD, AS, CrD, MS, PA, PAN, PSO, RA, SLE, T1D [63]
In sibling: AS, CrD
In parent and sibling: CrD, PSO
Crohn’s disease Hemminki et al. In parent: AS, PSO, UC [63]
In sibling: AS, UC
In parent and sibling: RA, UC
In twins: UC
Vitiligo Alkhateeb et al. AdD, AITD, MG, PA, SLE, SSc [64]
Laberge et al. AdD, AITD, PA, PSO, RA [65]
Zhang et al. AA, PSO, RA [66]
Juvenile rheumatoid arthritis Prahalad et al. AITD [67]
Huang et al. AITD, AS, PSO, SLE [68]
Juvenile lupus erythematosus Huang et al. AITD, AS, MG [68]
Inflammatory idiopathic myositis Ginn et al. AITD, PA, PSO, RA, SS, T1D [70]
Celiac disease Petaros et al. AITD, PSO, T1D [72]
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by Scofield et al. [82] while Corporaal et al. [44] found
clustering of MS and RA.
Rheumatoid arthritis
In RA, familial autoimmunity was ascertained in five
articles, all of which linked AITD or T1D to AR. Lin et
al. [45] showed an association with AITD in 7.8% of the
probands and T1D in 2.8%. Thomas et al. [46] also
reported T1D as the disease responsible for familial
autoimmunity. In another study, Taneja et al. [83] stated
that SLE, T1D, AITD, SS, PSO and systemic sclerosis
(SSc) were found in families with RA. However, they
included probands within this description, thus assessing
and combining polyautoimmunity or MAS with familial
autoimmunity. Walker et al. [84] found an excess risk
for AITD in RA multicase families compared with the
general population. However, this significance was lost
when RA sufferers were withdrawn from the analysis.
Jawaheer et al. [48] found the presence of AITD and
other ADs in siblings but, compared with siblings of
non-RA probands, the difference was not significant.
Hemminki et al. [47] also reported familial autoimmu-
nity in probands with RA. Just as described above, when
a parent had AS, the SIR for RA in offspring was 2.96.
It was 2.25 for SS, 2.13 for SLE, 1.65 for SSc, 1.54 for
AITD, 1.53 for PA, 1.36 for PSO and 1.34 for WG.
When singleton siblings had PSO, the SIR for RA of the
proband was 2.01 and 2.77 for SLE.
Multiple sclerosis
In our search, MS was the AD with the most articles
assessing familial autoimmunity with 10 articles found
[32,35,49-56]. Some studies suggest that FDRs and other
relatives of probands with MS could be at greater risk of
ADs other than MS [32,35,49-55,57] while the studies
done by Ramagopalan et al. [54] and Midgard et al. [85]
do not support these findings. Although Annunziata et
al. [86] found an association between MS and other
ADs in first and second degree relatives, the results
were not significant when compared to non-AD con-
trols. Conversely, Alonso et al. [87] and Magaña et al.
[88] found a significant association between MS and
other ADs in relatives of any degree.
Using 265 families from the Multiple Autoimmune
Disease Genetics Consortium (MADGC), Criswell et al.
[35] compared the frequency of ADs in siblings of mul-
tiplex families stratified by seven ADs: AITD, RA, MS,
SLE, T1D, IBD and PSO. These diseases were pre-speci-
fied given a variety of considerations. There was no evi-
dence of familial autoimmunity except in the case of
IBD patients in whose families MS was observed among
FDRs (OR: 8.1; 95% CI: 1.77 to 37.0; P value = 0.018).
However, selection bias was present as families selected
for inclusion were not recruited in the same manner
[35].
Meta-analyses
For the first effect size, OR, 13 meta-analyses were
developed. Ten analyzed the proportion of a specific AD
in FDRs independent of the AD present in the proband.
Of these, three showed significant association: AITD,
T1D and IBD. Three included an independent AD in
FDRs in a specific AD of the proband, two of them
showed significant associations: RA and MS. Figures 4
and 5 show the forest plots corresponding to six meta-
analyses.
A second effect size was calculated based on data
from studies showing RR data. Twenty eight meta-ana-
lyses were developed. Twenty three analyzed the propor-
tion of a specific AD in the FDR through all the studies
independent of any AD of the proband. Of these, nine-
teen showed significant association, the most relevant
results being related to VIT, PA, RA and T1D. Addi-
tional results are shown in Additional file 1. Through all
the studies, four additional analyses performed included
any AD present in FDRs. All these analysis disclosed
significant results. The ADs in the proband were AITD,
MS, RA and T1D (Figures 6 and 7).
Evidence of significant publication bias was identified
using the Egger test (P-value 2-tailed: <0.05) for two
meta-analyses which included studies that reported OR
with its respective 95% CI (T1D in FDR (P-value
2-tailed: 0.047) and MS in probands (P-value 2-tailed:
0.007)). One meta-analysis that reported RR data
showed publication bias by the Egger test (AITD in
probands (P-value 2-tailed: 0.008)) (Figure 6A). The
Table 1 Significant associations of autoimmune diseases in first degree relatives. (Continued)
Cataldo et al. AITD, T1D [73]
Neuhausen et al. JRA, T1D [74]
Alopecia areata Kakourou et al. AITD, CD, PSO, T1D, VIT [75]
AA, alopecia areata; AdD, Addison’s disease; AS, ankylosing spondylitis; AITD, autoimmune thyroid disease; CD, celiac disease; CrD, Crohn’s disease; IBD,
inflammatory bowel disease; IIM, idiopathic inflammatory myositis; JDM, juvenile dermatomyositis; JRA, juvenile rheumatoid arthritis; JSLE, juvenile systemic lupus
erythematosus; MAS, multiple autoimmune syndrome; MG, myasthenia gravis; MS, multiple sclerosis; PA, pernicious anemia; PAN, polyarteritis nodosa; PBC,
primary biliary cirrhosis; PSO, psoriasis; RA, rheumatoid arthritis; SLE, systemic lupus erythematosus; SS, Sjögren’s syndrome; SSc, systemic sclerosis; T1D, type 1
diabetes; UC, ulcerative colitis; VIT, vitiligo; WG, Wegener’s granulomatosis. Note: Although AS is considered an auto-inflammatory more than autoimmune
disease [76] we show the results obtained.
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Table 2 Characteristics of the studies included.
Disease in
probands
Author and
year
Country Study
type
Total
number of
probands
Affected
FDRs in
probands
Total
number
FDRs
Total
controls
Affected
FDRs in
controls
Total
FDRs in
controls
Oxford 2011
level of
evidence
Observations
AITD
Boelaert 2010
[33]
UK Cross
sectional
3286 845 6572 3
Hemminki
2009 [34]
Sweden Cohort 15,743 1,135 2,412 3
Criswell 2005
[35]
USA Cross
sectional
43 21 232 3
T1D
Criswell 2005
[35]
USA Cross
sectional
10 6 232 3
Bottazzo 1978
[36]
UK Cross
sectional
116 4 257 3
Anaya 2006
[37]
Colombia C&C 98 18 312 113 9 362 3
Wagner 2011
[38]
Spain Cross
sectional
12,973 97 1,279 3 Non diabetic siblings
12,973 1,001 6,262 Diabetic siblings
Hemminki
2009 [39]
Sweden Cohort 21,168 1,913 5,195 3
Samuelsson
2004 [40]
Lithuania/
Sweden
C&C 803 114 1,944 229 3 N = for controls and for FDRs is not specified
Lebenthal
2011a [41]
Israel Cross
sectional
121 57 3 Familial T1D patients
226 43 Sporadic T1D patients.
Numbers of FDRs are not given
SLE
Alarcón
Segovia 2005
[42]
Latin
america
Cross
sectional
1,177 50 3 Total number of FDRs is not specified
Priori 2003
[43]
Italy C&C 154 39 759 140 12 776 3
Corporaal
2002 [44]
The
Netherlands
Cross
sectional
135 42 693 3
Criswell 2005
[35]
USA Cross
sectional
65 47 232 3
RA
Criswell 2005
[35]
USA Cross
sectional
46 31 232 3
Lin 1998 [45] USA C&C 29 25 218 14 4 98 3
Thomas 1983
[46]
UK C&C 295 19 2,081 307 8 2,299 3
C
árdenas-Roldán
et
al.BM
C
M
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Table 2 Characteristics of the studies included. (Continued)
Hemminki
2009 [47]
Sweden Cohort 47,361 1,919 4,677 3
Jawaheer
2004 [48]
USA C&C 1,097 10 83 3 N = for controls and for total FDRs are not
specified
MS
Barcellos 2006
[32]
USA Cross
sectional
176 119 1,107 3
Criswell 2005
[35]
USA Cross
sectional
82 64 232 3
Broadley 2000
[49]
UK C&C 571 879 3,949 375 879 3949 3 Individual numbers of FDRs of cases and
controls are not given
Deretzi 2010
[50]
Greece C&C 891 410 3,112 355 96 1580 3
Heinzlef 2000
[51]
France Cross
sectional
357 33 1,971 4
Henderson
2000 [52]
Australia C&C 157 53 722 222 1582 1138 3
Marrosu 2002
[53]
Italy Cohort 1,090 53 5,480 3
Ramagopalan
2007 [54]
Canada Cross
sectional
5,031 786 30,259 3
Nielsen 2008
[55]
Denmark Cohort 8,205 260 20,800 3
Laroni 2005
[56]
Italy C&C 245 21 984 245 13 1,002 4
SSc
Arora Singh
2010 [57]
USA 1,071 184 4,612 3
Hudson 2008
[58]
Canada Cross
sectional
719 260 715 3
Koumakis
2012 [59]
France C&C 373 245 823 250 70 318 3
Frech 2010
[60]
USA Nested
C&C
1,037 95 4,629 10,370 417 49,312 3 Total number of FDRs, from controls, is not
specified but ten controls were selected per
proband
SS
Reveille 1984
[61]
USA Cross
sectional
98 3 Total number of FDRs and affected FDRs are
not specified
Anaya 2006
[62]
Colombia C&C 101 56 876 124 33 857 3
UC
Hemminki
2010 [63]
Sweden Cohort 25,846 2,528 5,121 3
CrD
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Table 2 Characteristics of the studies included. (Continued)
Hemminki
2010 [63]
Sweden Cohort 18,885 2,169 4,306 3
IBD
Criswell 2005
[35]
USA Cross
sectional
7 8 232 3
VIT
Alkhateeb
2003 [64]
USA/UK Cross
sectional
2,624 660 8,034 3
Laberge 2005
[65]
USA Cross
sectional
133 98 331 3
Zhang 2009
[66]
China Cross
sectional
5,601 340 18,705 3
JRA
Prahalad 2002
[67]
USA C&C 110 72 446 45 29 181 3
Huang 2004
[68]
Taiwan Cross
sectional
110 5 3 Total number of FDRs is not specified
JSLE
Huang 2004
[68]
Taiwan Cross
sectional
91 6 3 Total number of FDRs is not specified
Walters 2012
[69]
USA Cross
sectional
69 23 3 Total number of FDRs is not specified
IIM
Ginn 1998
[70]
USA C&C 21 33 151 21 7 143 3
Niewold 2011
[71]
USA Cross
sectional
304 30 1,224 3
CD
Petaros 2002
[72]
Italy C&C 125 18 373 125 4 352 3
Cataldo 2003
[73]
Italy C&C 66 11 225 68 2 232 3
Neuhausen
2008 [74]
USA Cross
sectional
408 58 1,272 3
AA
Kakouroru
2007 [75]
Greece C&C 157 100 3 Total number of FDRs and affected FDRs are
not specified
PSO
Criswell 2005
[35]
USA Cross
sectional
8 8 232 3
aNumbers depicted represent families and not family members. Note: Only classical ADs are taken into account. Although some studies did not report the number of FDRs they specified other measures of
association. See text for more details. AA, alopecia areata; AITD, autoimmune thyroid disease; C&C, case control; CD, celiac disease; CrD, Crohn’s disease; IBD, inflammatory bowel disease; IIM, idiopathic inflammatory
myositis; JRA, juvenile rheumatoid arthritis; JSLE, juvenile systemic lupus erythematosus; MS, multiple sclerosis; PSO, psoriasis; RA, rheumatoid arthritis; SLE, systemic lupus erythematosus; SS, Sjögren’s syndrome; SSc,
systemic sclerosis; T1D, type 1 diabetes; UC, ulcerative colitis; VIT, vitiligo.
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corresponding funnel plot showing the standard error or
the precision on the Y axis is shown in Additional file 2.
Therefore, a second analysis was run in a search for
publication bias. The classic fail-safe analysis indicated a
number of missing studies that would give a P-value of
>0.05. Begg and Mazumdar rank correlation was not
significant and the trim and fill adjustment did not sug-
gest a lower risk than the original analysis. Based on all
Figure 4 Forest plots depicting odds ratios for specific autoimmune diseases in first degree relatives. Familial autoimmunity has to be
seen as a two way relationship depending on which member of the nuclear family is the proband. Therefore, grouping meta-analysis by the
disease present in FDRs is equivalent to analyzing it by the disease present in the proband. The figure shows four different analyses. From top to
bottom autoimmune thyroid disease (A), type 1 diabetes mellitus (B), inflammatory bowel disease (C) and familial autoimmunity (D) assessed as
an outcome. The summary effect (random effect model) is depicted as a diamond at the bottom of each analysis. The lateral points of each
diamond indicate confidence intervals for this estimate. aNumbers represent different subgroups within the study.
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the analyses for publication bias, we consider the impact
of bias in the three meta-analyses to be trivial.
Familial autoimmunity as an outcome was also
assessed in certain articles, particularly in MS and SLE
probands (Figure 4D).
Aggregation
Several studies retrieved only reported prevalences of
ADs in FDRs. Aggregation, based on data from five stu-
dies mentioned earlier in Table 3[2,29-32], is shown in
Table 4, which discloses information on calculated
Figure 5 Forest plots depicting odds ratios for familial autoimmunity. The figure shows two different analyses. From top to bottom:
(A) rheumatoid arthritis (RA), (B) multiple sclerosis (MS). Autoimmune diseases in first degree relatives through all the studies from a specific
autoimmune disease present in the proband were analyzed. The summary effect (random effect model) is depicted as a diamond at the bottom
of each analysis. The lateral points of each diamond indicate confidence intervals for this estimate. aNumbers represent different subgroups
within the study.
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Figure 6 Forest plots depicting risk ratios for familial autoimmunity in probands with AITD and MS. The figure shows two different
analyses. From top to bottom: autoimmune thyroid disease (A) and multiple sclerosis (B). The summary effect (random effect model) is depicted
as a diamond at the bottom of each analysis. The lateral points of each diamond indicate confidence intervals for this estimate. aNumbers in the
study name represent different subgroups within the study. AITD, autoimmune thyroid disease; MS, multiple sclerosis.
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Figure 7 Forest plots depicting risk ratios for familial autoimmunity in probands with T1D and RA. The figure shows two different
analyses. From top to bottom: type 1 diabetes mellitus (A) and rheumatoid arthritis (B). The summary effect (random effect model) is depicted
as a diamond at the bottom of each analysis, the lateral points of which indicate confidence intervals for this estimate. aNumbers in the study
name represent different subgroups within the study. RA, rheumatoid arthritis; T1D, type 1 diabetes.
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aggregation for diverse ADs, in AITD, T1D, SLE, RA
and MS.
Other autoimmune diseases
The systematic search we performed retrieved other stu-
dies that assessed familial autoimmunity besides the five
ADs we were focused on. These ADs are SSc, SS, IBD,
juvenile dermatomyositis (JDM), VIT, juvenile rheuma-
toid arthritis (JRA), juvenile SLE (JSLE), idiopathic
inflammatory myositis (IIM), CD, and alopecia areata
(AA).
Systemic sclerosis
Four studies reported diagnosis of AITD, RA and SLE in
FDRs of SSc probands [57-60]. Frech et al. [60] found a
RR of 2.49 (95% C.I. 1.99 to 3.41) for familial autoim-
munity in FDRs and a RR of 1.48 (95% C.I.1.34 to 2.39)
for familial autoimmunity in second degree relatives.
Sjögren´s syndrome
Two studies were found on this disease, one by Reveille
et al. [61] and the other done by our group [62]. Both
studies agreed on the occurrence of AITD and SLE
among relatives. In addition to these ADs, we described
the presence of RA [62] while Reveille et al. [61]
reported the occurrence of MS and SSc.
Inflammatory bowel disease
Two studies were retrieved. As mentioned earlier, Criswell
et al. [35] found an increased frequency of familial autoim-
munity among probands with IBD. A study conducted by
Hemminki et al. [63] assessed familial autoimmunity
within IBD probands. In UC patients when a parent had
AS the SIR for UC in offspring was 1.6, for Crohn’s disease
(CrD) 2.5, for T1D 1.2, for Graves’ disease 1.3, for MS 1.4,
for polyarteritis nodosa (PAN) 2.0, for PSO 1.3, for RA
1.1, and for SLE 1.5 [63]. When singleton siblings had CD,
the SIR for UC was 2.5, and for AS was 2.1. When a par-
ent and a sibling had CrD the SIR for UC was 4.7 and for
PSO was 4.3. In CrD patients, when a parent was diag-
nosed with UC, the SIR for CrD in offspring was 2.4, for
AS was 1.8 and for PSO was 1.4. When singleton siblings
had UC, the SIR was 2.8 and for AS was 2.1. When a par-
ent and a sibling had UC, the SIR for CD was 5.0 and for
RA was 2.2. In twins, the SIR for CrD-UC pairs was
4.9 [63].
Vitiligo
For VIT, three studies assessed familial autoimmunity.
The studies done by Alkhateeb et al. [64] and Laberge
et al. [65] discovered a significant increase in the occur-
rence of three ADs other than VIT, namely, AITD, PA
and AdD. Alkhateeb et al. also reported the occurrence
of SLE, myasthenia gravis (MG) and SSc [64], while
Laberge et al. found the presence of PSO and RA [65].
In Chinese patients, Zhang et al. [66] found a significant
association with RA, AA and PSO.
Juvenile rheumatoid arthritis
Two studies were found on familial autoimmunity in JRA
[67,68]. Prahalad et al. [67] found that AITD accounted
for the familial autoimmunity seen in these probands.
Huang et al. [68] found, in addition to AITD, the presence
of PSO, AS and SLE. Furthermore, Huang et al. [68] com-
pared the prevalence of ADs in family members of pro-
bands with JRA against the prevalence in family members
of probands with JSLE. Including all family members (that
is, first, second and third degree relatives), JSLE probands
had a greater prevalence of familial autoimmunity than
probands with JRA. Nonetheless, in FDR the prevalence of
ADs was not significantly different between these two dis-
eases. Thus, familial autoimmunity is equally present in
JRA and JSLE. Likewise, Pachman et al. [89] compared
JRA to JDM and to healthy controls. The only statistically
significant association was an increased frequency of RA
and PA in FDR of JRA probands.
Table 3 Prevalence of specific autoimmune diseasesa
Autoimmune disease Prevalence (%)
Any autoimmune disease 3 to 8
Addison’s disease 0.009
Alopecia areata 0.15
Ankylosing spondylitis 0.20
Autoimmune hepatitis ≤0.001
Celiac disease 0.75
CREST syndrome ≤0.001
Diabetes (type 1) 0.190
Graves’ disease 1.200
Hashimoto’s thyroiditis 0.800
Idiopathic thrombocytopenic purpura ≤0.001
Inflammatory bowel disease 0.450
Juvenile idiopathic arthritis 0.148
Multiple sclerosis 0.058
Myasthenia gravis 0.005
Pernicious anemia 0.150
Polymyositis/dermatomyositis 0.005
Primary biliary cirrhosis 0.004
Psoriasis 0.75
Rheumatoid arthritis 1
Sjögren’s syndrome 0.3
Systemic lupus erythematosus 0.024
Systemic sclerosis (scleroderma) 0.004
Vitiligo 0.4
Wegener’s granulomatosis 0.003
aPrevalences according to [2,29-32]. CREST, Calcinosis, Raynaud phenomenon,
esophageal dysmotility, sclerodactyly, and telangiectasia.
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Table 4 Aggregation of ADs.
Disease in probands
T1D AITD SLE RA MS
AD in FDRs USA
[35]
UK
[36]
Colombia
[37]
Spain
[38]
Swed/
Lith
[40]
UK
[33]
USA
[35]
USA
[35]
Latin
America
[42]
NL
[44]
USA
1
[35]
USA
2
[45]
UK
[46]
USA
3
[48]
USA1
[32]
USA
2
[35]
USA
3
[87]
Greece
(Multiplex)
[50]
Greece
(Simplex)
[50]
Australia
[52]
Italy
(Multiplex)
[53]
Italy
(Simplex)
[53]
Canada
[54]
AITD 11.11 0.98 2.4 4.6 0.88 21.7 16 20 14.7 3.9 4.81 5.50 13,28
Hyperthyroidisma 4.2 3.75 22.1 9.42 8.2 14.15
Hypothyroidism
a
7.38 1.71 0.74 9.43
T1D 13.5 7.53 78.9 39.7 12.53 30.9 14.49 74 93.2 14.41 5.41 49.65 11.70 3.51 1.93
RA 0.9 7.41 22.5 16.98 64 28.57 2.0 7.8 18.7 0.68 0.18 20.75 1.73
PA 2.14 12.38
SLE 462 13.35 5.71 312.5 595 163.4 390 225 42.8 25 471
AdD 4.81
CD 3.6 0.54 0.39
VIT 0.8 2.75 1.6 0.86 0.09 4.72
MS 7.61 86.2 130 164 67.6
MG 9.13 9.17 68.49 7.09
IBD 0.89 1.25 30 4.2 21.79 4.44 24 10.9 7.38 15.09
PSO 14.8 1.6 10 15.69 2.67 25 5.48 1.77 33.9
SS 7.9 6.85 1.77
AS 2.29 56.6
SSc 500 595 471
IIM 400
Table shows aggregation (l) of ADs. The top row depicts the AD present in the proband while the first column shows the AD present in FDRs. The numbers correspond to the calculation of aggregation. aOnly autoimmune
hypothyroidism and hyperthyroidism are depicted. Prevalences in the general population according to [2,29-32]. If a range was reported the mean was calculated. AdD, Addison’s disease; AS, ankylosing spondylitis; AITD,
autoimmune thyroid disease; CD, celiac disease; IBD, inflammatory bowel disease; IIM, idiopathic inflammatory myositis; Lith, Lithuania; MG, myasthenia gravis; MS, multiple sclerosis; NL, The Netherlands; PA, pernicious anemia;
PSO, psoriasis; RA, rheumatoid arthritis; SLE, systemic lupus erythematosus; SS, Sjögren’s syndrome; SSc, systemic sclerosis; Swed, Sweden; T1D, type 1 diabetes; VIT, vitiligo.
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Juvenile systemic lupus erythematosus
Two articles were found for this disease. While Huang et
al. [68] found that 17% of the FDRs of JSLE probands
were affected with an AD, Walters et al. [69] found a pre-
valence of 51%, with 35% of FDRs from JSLE probands
having SLE, 30% AITD and 13% PSO.
Idiopathic inflammatory myositis
Familial autoimmunity has also been assessed for IIM in
two studies. The study by Ginn et al. [70] found that the
most common disease was, once again, AITD followed
by RA, T1D and PSO. In this article, OR for familial
aggregation of ADs was calculated irrespective of disease
status (that is, case or control). The strongest predictors
were a blood relative and female gender. Niewold et al.
[71] reported that FDRs of probands with JDM had a
higher frequency of T1D or SLE than in FDRs of con-
trols. However, this relationship did not reach statistical
significance.
Celiac disease
Three articles were found. Petaros et al. [72] found that
the prevalence of familial autoimmunity was 4.9% among
first and second degree relatives. The ADs that became
manifest were AITD, PSO and T1D. In line with these
results, Cataldo et al. [73] found an increased prevalence
of ADs including AITD and T1D. Neuhausen et al. [74]
also found a significant association with T1D and JRA.
However, contrary to what was expected, they found a
decreased prevalence of AITD.
Alopecia areata
An increased frequency of AITD, VIT, T1D, PSO, and CD
was found among FDRs of pediatric patients with AA [75].
Discussion
The results found in this work support aggregation of
diverse ADs (that is, familial autoimmunity) and the view
of a common origin for ADs (that is, the autoimmune tau-
tology). While polyautoimmunity [7-9,90,91] and familial
autoimmune disease [1,9,42,92-94] are well-supported
concepts in the medical literature, few articles have famil-
ial autoimmunity as their primary concern. Familial auto-
immunity is still a topic that has not been thoroughly
explored. To our knowledge, this is the first study specifi-
cally designed as a systematic review and meta-analysis to
find evidence for familial autoimmunity in five major ADs.
Familial autoimmunity uses the concept of ‘autoimmune
disease’ as a trait that encompasses all pathologies showing
evidence of an autoimmune origin. AITD followed by
SLE and RA were the most frequent ADs encountered
(Figure 8).
Our meta-analysis was developed in two stages. First,
we wanted to determine the presence of familial autoim-
munity as a trait in probands with the five index diseases
mentioned earlier. However, a meta-analysis of studies
having probands with SLE was not feasible. For the other
four index diseases the meta-analyses indicate an
increased risk of familial autoimmunity with RRs of 2.4,
1.6, 1.5, and 1.3 for AITD, T1D, RA and MS, respectively.
It is not surprising to have AITD as the disease with a
greater risk for familial autoimmunity as it is the most
common AD worldwide. Meta-analyses with ORs as a
measure of association were also done showing a signifi-
cant relationship of familial autoimmunity with RA and
MS probands.
Conversely, for our second approach, instead of group-
ing the studies for the meta-analyses by the proband’s
disease, we grouped the studies according to the disease
Figure 8 Familial autoimmunity. The vertical axis corresponds to the proband’s disease and each disease individually. In the horizontal axis
diseases present in first degree relatives are shown. Each color belongs to the proband’s disease. The figure only includes significant results and
may serve as a guide for clinical practice in order to search ADs in FDRs of probands. Note that familial autoimmune disease is excluded. AA,
alopecia areata; AdD, Addison’s disease; AS, ankylosing spondylitis; AITD, autoimmune thyroid disease; CD, celiac disease; CrD, Crohn’s disease;
FDR, first degree relative; IBD, inflammatory bowel disease; IIM, idiopathic inflammatory myositis; JDM, juvenile dermatomyositis; JRA, juvenile
rheumatoid arthritis; JSLE, juvenile systemic lupus erythematosus; MAS, multiple autoimmune syndrome; MG, myasthenia gravis; MS, multiple
sclerosis; PA, pernicious anemia; PAN, polyarteritis nodosa; PBC, primary biliary cirrhosis; PSO, psoriasis; RA, rheumatoid arthritis; SLE, systemic
lupus erythematosus; SS, Sjögren’s syndrome; SSc, systemic sclerosis; T1D, type 1 diabetes; UC, ulcerative colitis; VIT, vitiligo; WG, Wegener’s
granulomatosis. Note: Although AS is considered an auto inflammatory more than autoimmune disease [76] we show the results obtained.
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present in FDRs. We must look at familial autoimmunity
as a two way relationship depending upon which member
of the nuclear family is the proband. Accordingly, we
developed our second approach which also disclosed the
presence of familial autoimmunity in a variety of ADs
(Figure 4 and Additional file 1).
Several reasons may account for the heterogeneity
found in our study, which have been also acknowledged
by other authors [90,95], namely, different study designs,
geographical differences, lack of adequate controls, use
of a selected group of probands, and information bias,
that is, recall bias [96], diverse population characteris-
tics, and assorted study dates. The quality of studies was
certainly influenced by the lack of awareness of familial
autoimmunity. In addition, with time diagnostic
approaches may have a better performance which may
lead to a false increase in diagnoses frequencies.
Aggregation analyses disclosed extreme values (Table 3
and Table 4), with familial recurrence risk values over
100 as in the case of SSc (l for SSc in FDRs of SLE pro-
bands = 500 to 595) or the case for SLE (l for SLE in
FDRs of MS probands = 471). In addition to these
extreme values, we had conflicting results as in the case
between MS and RA, and T1D and AITD for which
some studies found a lack of aggregation whereas others
found the opposite. These discrepancies may be
explained by the fact that there are differences in preva-
lence according to geographical location, that aggregation
involves genetic and environmental factors and, also, by
the arbitrary calculation of means whenever a prevalence
range was reported.
In the clinical setting, clinicians should be aware of
familial autoimmunity whenever they are attending
patients with ADs (Figure 8). A search for autoimmunity
in their FDRs should be encouraged by exploring the
presence of auto-antibodies [5] and other risk factors
[20,21]. Since healthy subjects may have positive autoan-
tibody titers, we decided only to include studies that
were based on clinical diseases and not on the presence
of autoantibodies.
ADs follow a multifactorial (or complex) inheritance
pattern which represents an interaction between the col-
lective effect of the genotype at multiple loci (polygenic
or multigenic effects) either to raise or to lower suscept-
ibility to disease, combined with a variety of environ-
mental exposures that may trigger, accelerate,
exacerbate, or protect against the disease process.
Besides assessing the increased frequency of familial
autoimmunity, the search also retrieved studies describ-
ing how this familial autoimmunity presents. A predo-
minant inheritance of the autoimmunity trait from
mothers was evident in some ADs including SS [62],
juvenile idiopathic arthritis [97] and T1D [40]. This is
indicative of a preferential transmission of susceptibility
alleles from mothers to offspring. Maternal transmission
of autoimmunity could be influenced by the high pre-
ponderance of ADs in women as compared with the
general population. However, this higher than expected
frequency of maternal transmission of the autoimmunity
trait would warrant further studies of mitochondrial
DNA, genomic imprinting, maternal-offspring compat-
ibility, gene-environment and indirect genetic effects in
ADs [62].
Another factor that influences familial autoimmunity is
race [40,98,99]. Houghton et al. [98] compared the preva-
lence of familial autoimmunity between ‘native’ (Amerin-
dian) and other groups in pediatric patients in the United
States. In a small sample (6 Amerindians with SLE versus
34 non Amerindian population with SLE ), 83% of the
native probands had a familial history of ADs while this
was true for only 19% of the non-natives [98]. Mean-
while, with a larger sample size, the GLADEL study
found that mestizos had more familial autoimmunity
than other racial groups [42]. In fact, ancestry influences
the risk and outcome of autoimmunity [99].
We would like to acknowledge the limitations of our
study. First, the search was focused on five principal
ADs, but we identified articles with probands from
other ADs. It is probable that the number of articles
retrieved from these ADs is less than if a specific search
was done for each of these diseases. Second, we recall
the heterogeneity of the study [100,101]. Third, in our
search we found articles that did not distinguish
between the presence of autoantibodies and a clinical
diagnosis of an AD. This also should be taken into
account in future studies as the presence of autoantibo-
dies may occur in healthy people. Nevertheless, as stated
earlier, they may herald a later onset of a given AD and,
therefore, it may be clinically important to follow up
those individuals.
Conclusions
The importance of familial autoimmunity has been shown
[102]. AITD followed by SLE and RA are the most fre-
quent ADs in familial autoimmunity. Although non-
genetic factors may have an effect on familial aggregation,
shared genetic factors, in fact, may be the more likely
cause for this aggregation [9]. Genes with larger effects
(higher penetrance) are related to Mendelian patterns of
inheritance, whereas those with smaller effects (lower
penetrance) are related rather to complex traits, such as
ADs. Identification of such genes, predisposing and affect-
ing the outcome of ADs, is a major challenge for the near
future. Given the clinical and etiologic heterogeneity of
ADs, understanding the relationship of genotype to phe-
notype is an extremely important goal for research aimed
at gene identification. Thus, further studies of familial
autoimmunity will help in increasing the knowledge about
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the common mechanisms of autoimmunity. Genomics
and other related disciplines will offer the tools to accom-
plish this task, allowing us to predict and prevent ADs, tai-
lor individual medical decisions, and provide personalized
healthcare while facilitating the patients’ participation in
their treatment and eventual cure of their disease [103].
Additional material
Additional file 1: Forest plots depicting risk ratios for familial
autoimmunity in first degree relatives. The figure shows two different
analyses. From top to bottom: Addison’s disease, autoimmune thyroid
disease, ankylosing spondylitis, celiac disease, inflammatory bowel
disease, discoid lupus, hemolytic anemia, inflammatory idiopathic
myositis, immune thrombocytopenic purpura, localized scleroderma,
pernicious anemia, myasthenia gravis, multiple sclerosis, polyarteritis
nodosa, primary biliary cirrhosis, psoriasis, rheumatoid arthritis, systemic
lupus erythematosus, Sjögren’s syndrome, systemic sclerosis, type 1
diabetes, vitiligo, Wegener’s granulomatosis. The summary effect (random
effect model) is depicted as a diamond at the bottom of each analysis.
The lateral points of each diamond indicate confidence intervals for this
estimate.
Additional file 2: Funnel plots of the three meta-analyses showing
publication bias. The corresponding funnel plot shows the standard
error on the Y axis and the log value for common effect size on the
horizontal axis. From top to bottom: OR for Type 1 diabetes in first
degree relatives, OR for multiple sclerosis in probands, RR for
autoimmune thyroid disease in probands. Visual inspection of funnel
plots suggested effect sizes for the mentioned analyses were scattered
asymmetrically around a central effect. OR, odds ratio; RR, risk ratio.
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